These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 26864592)

  • 1. Vismodegib and Physeal Closure in a Pediatric Patient.
    Lucas JT; Wright KD
    Pediatr Blood Cancer; 2016 Nov; 63(11):2058. PubMed ID: 26864592
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study.
    Gajjar A; Stewart CF; Ellison DW; Kaste S; Kun LE; Packer RJ; Goldman S; Chintagumpala M; Wallace D; Takebe N; Boyett JM; Gilbertson RJ; Curran T
    Clin Cancer Res; 2013 Nov; 19(22):6305-12. PubMed ID: 24077351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly(2-oxazoline) nanoparticle delivery enhances the therapeutic potential of vismodegib for medulloblastoma by improving CNS pharmacokinetics and reducing systemic toxicity.
    Hwang D; Dismuke T; Tikunov A; Rosen EP; Kagel JR; Ramsey JD; Lim C; Zamboni W; Kabanov AV; Gershon TR; Sokolsky-Papkov PhD M
    Nanomedicine; 2021 Feb; 32():102345. PubMed ID: 33259959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early and persisting response to vismodegib in a patient with bone metastasizing medulloblastoma.
    Asklund T; Henriksson R; Axelsson J; Bergström Å; Kasper M; Ögren M; Toftgård R; Riklund KÅ
    Acta Oncol; 2013 May; 52(4):862-6. PubMed ID: 23013267
    [No Abstract]   [Full Text] [Related]  

  • 5. Possible mechanisms and biomarkers of resistance to vismodegib in SHH medulloblastoma.
    Roesler R; de Farias CB; Brunetto AT; Gregianin L; Jaeger M; Nör C; Thomaz A
    Neuro Oncol; 2022 Jul; 24(7):1210-1211. PubMed ID: 35552442
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
    Li Y; Song Q; Day BW
    Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged response to vismodegib in a patient with systemic medulloblastoma metastases.
    Climans SA; Macdonald DR; Sutherland DE; Mason WP
    BMJ Case Rep; 2020 Oct; 13(10):. PubMed ID: 33122230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition.
    Metcalfe C; Alicke B; Crow A; Lamoureux M; Dijkgraaf GJ; Peale F; Gould SE; de Sauvage FJ
    Cancer Res; 2013 Dec; 73(23):7034-42. PubMed ID: 24154871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SHH inhibitors for the treatment of medulloblastoma.
    Samkari A; White J; Packer R
    Expert Rev Neurother; 2015; 15(7):763-70. PubMed ID: 26027634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Therapy Makes Inroads in Medulloblastoma.
    Schmidt C
    J Natl Cancer Inst; 2015 Nov; 107(11):djv353. PubMed ID: 26538622
    [No Abstract]   [Full Text] [Related]  

  • 11. Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity.
    Lu W; Liu Y; Ma H; Zheng J; Tian S; Sun Z; Luo L; Li J; Zhang H; Yang ZJ; Zhang X
    ACS Chem Neurosci; 2017 Sep; 8(9):1980-1994. PubMed ID: 28618224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New-Onset Congestive Heart Failure in a Patient on Vismodegib.
    Huizenga T; Newsom E; Fakhouri T; Kado J
    Dermatol Surg; 2015 Nov; 41(11):1329-32. PubMed ID: 26458043
    [No Abstract]   [Full Text] [Related]  

  • 13. Persistent alopecia induced by vismodegib.
    Alkeraye S; Maire C; Desmedt E; Templier C; Mortier L
    Br J Dermatol; 2015 Jun; 172(6):1671-1672. PubMed ID: 25546344
    [No Abstract]   [Full Text] [Related]  

  • 14. Acute pancreatitis after vismodegib for basal cell carcinoma: a causal relation?
    Velter C; Blanc J; Robert C
    Eur J Cancer; 2019 Sep; 118():67-69. PubMed ID: 31325874
    [No Abstract]   [Full Text] [Related]  

  • 15. Reversible cutaneous side effects of vismodegib treatment.
    Kwong B; Danial C; Liu A; Chun KA; Chang AL
    Cutis; 2017 Mar; 99(3):E19-E20. PubMed ID: 28398426
    [No Abstract]   [Full Text] [Related]  

  • 16. Four-year experience with vismodegib hedgehog inhibitor therapy.
    Simone PD; Schwarz JM; Strasswimmer JM
    J Am Acad Dermatol; 2016 Jun; 74(6):1264-5. PubMed ID: 27185433
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug reaction with eosinophilia and systemic symptoms in metastatic basal cell carcinoma treated with vismodegib.
    Thomas CL; Arasaratnam M; Carlos G; Parasyn A; Baumgart KW; Fernandez-Penas P; Marx G
    Australas J Dermatol; 2017 Feb; 58(1):69-70. PubMed ID: 28195319
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449.
    Rudin CM; Hann CL; Laterra J; Yauch RL; Callahan CA; Fu L; Holcomb T; Stinson J; Gould SE; Coleman B; LoRusso PM; Von Hoff DD; de Sauvage FJ; Low JA
    N Engl J Med; 2009 Sep; 361(12):1173-8. PubMed ID: 19726761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Report of cutaneous side effects of vismodegib treatment.
    Caplash G; Curragh DS; Halliday L; Huilgol SC; Selva D
    Clin Exp Ophthalmol; 2020 Jan; 48(1):123-125. PubMed ID: 31569297
    [No Abstract]   [Full Text] [Related]  

  • 20. Cannabis for Vismodegib-Related Muscle Cramps in a Patient With Advanced Basal Cell Carcinoma.
    Kutiel TS; Vornicova O; Bar-Sela G
    J Pain Symptom Manage; 2018 May; 55(5):e1-e2. PubMed ID: 29454899
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.